Price movement over the last 24 hours
Alcon AG vs Carlyle Group Inc — how do they compare? Alcon AG trades at $66.86 (market cap $32.69B), while Carlyle Group Inc trades at $43 (market cap $15.84B). The key difference: Alcon AG is far larger — about 2.1× Carlyle Group Inc's market cap, and Carlyle Group Inc pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| ALC | CG | |
|---|---|---|
Market Cap | $32.69B | $15.84B |
Sector | Health | Financials |
52-Week High | $92.22 | $69.35 |
52-Week Low | $62.02 | $40.52 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | 3.18% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Carlyle Group (CG) trades at $44.01, up 2.76% with a P/E of 30.16 and P/S of 5.61. Recent earnings show mixed results with Q4 2025 beat but Q1 2026 miss. Technical indicators signal bearish momentum with RSI at 76.93 suggesting overbought conditions. The company maintains strong analyst support with 14 buy ratings and a $59.60 consensus price target, representing 35% upside potential from current levels.
Carlyle demonstrates solid profitability with 18.85% net margin and 9.95% ROE, though revenue declined to $3.21B in 2025. Key risks include volatile cash flow from operations and execution challenges in fundraising targets. The stock offers growth potential through strategic acquisitions like MAI Capital Management, but investors should monitor earnings consistency and private credit exposure.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →